Educational information only. Not medical advice.

Research Memos

TB-500 vs GHK-Cu

Analytical studies identify TB-500 as the acetylated seven-amino-acid thymosin β4 fragment Ac-LKKTETQ. GHK-Cu is a copper-bound tripeptide studied in specific skin and wound preparations. TB-500 fragment findings involve analytical and cell studies; GHK-Cu has mixed human topical findings. Full-length thymosin β4 trials and ambiguously named products cannot establish a fragment-versus-GHK-Cu clinical ranking.

Research reviewed October 15, 2026. Educational information only.

The TB-500 name needs a sequence

Independent product-analysis studies identified TB-500 as Ac-LKKTETQ, a seven-amino-acid fragment with an acetyl group at its amino end. FDA’s 2026 assessment distinguishes its free base from the acetate salt. The full-length parent, thymosin β4, has 43 amino acids. Unacetylated LKKTETQ and shorter breakdown products are additional materials. Their different chains and modifications affect which experiment can support which claim.

GHK-Cu contains the three-amino-acid peptide glycyl–histidyl–lysine coordinated with copper. Its chemistry and topical-formulation evidence developed separately. Neither a broad “repair peptide” label nor the use of both names on a mixture establishes equivalent action or a direct clinical comparison.

The main differences

What material does each name identify?

The exact chain and chemical form determine which experiments belong in the comparison.

TB-500

Analytical studies identified Ac-LKKTETQ, an N-acetylated seven-residue thymosin β4 fragment, in examined TB-500 products. The 43-residue parent, unacetylated LKKTETQ and acetate salt require separate identification. A supplier name alone does not characterize a new product.

Sources

GHK-Cu

GHK-Cu consists of glycyl–histidyl–lysine coordinated with copper. Solution studies describe multiple copper-containing species. The full tested formula, rather than the peptide name alone, defines a topical experiment.

Sources

What did the repair-related cell tests find?

Fibroblasts are connective-tissue cells that produce structural proteins. A scratch assay measures closure of a gap in a cell layer. A collagen assay measures production of a structural protein. These are different tests, without a shared effect scale.

TB-500

Rahaman and colleagues tested the acetylated fragment and metabolites in cultured fibroblasts. Only Ac-LKKTE, a five-residue breakdown product, clearly increased gap closure relative to the assay control. The parent Ac-LKKTETQ did not establish that increase; the abstract does not specify the control’s ingredients.

Sources

GHK-Cu

Maquart and colleagues found that GHK-Cu-exposed fibroblasts made more collagen without an increase in cell number. It was a culture experiment, without measurement of human wound strength, closure time or wrinkle appearance.

Sources

Which forms have clinical wound or skin results?

A trial of the full-length thymosin parent cannot establish an effect of its acetylated fragment. Human topical GHK-Cu findings remain tied to the tested wound and formula.

TB-500

FDA’s 2026 assessment did not identify patient studies demonstrating wound-healing effectiveness of the defined acetylated fragment. Full-length thymosin β4 reports and a rat tendon paper with unresolved supplier-product identity do not supply a fragment-specific human result.

Sources

GHK-Cu

In the diabetic-ulcer study, ulcers on the soles of the feet shrank by a median 98.5% with GHK-copper gel versus 60.8% with comparison gel without GHK-Cu. The abstract omits the patient count, assessment time and confidence interval. A separate venous-ulcer trial did not establish an advantage of copper cream over cream without peptide. These mixed results do not establish a benefit over TB-500.

Sources

What does detection tell us about persistence?

A metabolite in rat urine and copper crossing removed human skin are different analytes and systems. Neither measurement establishes a human blood half-life of the intact compound.

TB-500

Ac-LKK, one breakdown product, was detected in rat urine through 72 hours. The scratch-assay activity involved a different product, Ac-LKKTE. A detection window does not establish parent-peptide half-life or how long an active metabolite reaches an injured tissue.

Sources

GHK-Cu

After application of a copper–GHK preparation to removed human skin, copper crossed and remained in skin over 48 hours. The metal assay did not establish intact GHK-Cu transport or concentrations in a treated person’s blood.

Sources

Can their safety be compared from these sources?

The safety observations concern different preparations, routes and study settings; there is no direct comparative rate estimate.

TB-500

FDA’s 2026 assessment found insufficient clinical safety information for TB-500 free base and acetate. It raised possible immune-reaction risks associated with aggregation and peptide impurities. Cell-assay tolerability and full-length-parent studies do not establish the fragment’s human safety.

Sources

GHK-Cu

FDA’s safety-risk entry specifically addresses injectable GHK-Cu and cites limited human data and possible immune reactions related to aggregation and peptide impurities. Topical trials cannot establish injection safety or a lower long-term risk than TB-500.

Sources

One TB-500 breakdown product closed a cell-layer gap more clearly

Rahaman and colleagues (2024) measured breakdown of the acetylated fragment in laboratory systems and rats. In a separate scratch assay, they created a gap in a layer of fibroblasts and compared the parent peptide with its breakdown products. Only Ac-LKKTE produced a statistically clear increase in closure relative to the assay control. The parent Ac-LKKTETQ did not establish that increase. The accessible abstract does not describe the control composition or provide the full effect estimates.

That result raises a specific biological question: would the active breakdown product be formed and reach an injured tissue at a relevant concentration? Gap closure in a cell layer cannot answer it. Full-length thymosin β4’s actin biology likewise cannot be assigned wholesale to a seven-residue fragment.

Maquart and colleagues (1988) found increased collagen production in fibroblasts exposed to GHK-Cu, without increased cell number. This measured production of a structural protein. The TB-500 scratch assay measured closure of a cell-layer gap. The two experiments offer different observations and supply no comparative effect size.

GHK-Cu has human topical trials with different results

Mulder and colleagues (1994) studied GHK-copper gel in diabetic neuropathic ulcers during standardized wound care. Plantar ulcers, on the sole of the foot, had median area reduction of 98.5% with copper gel versus 60.8% with comparison gel without GHK-Cu (P<0.05). These percentages describe reduction of ulcer area. The abstract leaves the participant denominator, assessment time and confidence interval unspecified.

Bishop and colleagues (1992) reported 86 evaluable completers in a randomized venous-ulcer trial. Copper-tripeptide cream did not establish greater ulcer-size reduction than the cream without peptide; silver sulfadiazine reduced size more than either. A separate post-laser trial by Miller and colleagues (2006) had thirteen completers: objective redness, wrinkle and skin-quality measures did not establish a GHK-Cu advantage, while patient-rated skin quality favored it (P=0.04). The patient, product and outcome explain why a single general claim about skin repair would be misleading.

FDA’s 2026 TB-500 evaluation did not identify patient studies establishing effectiveness of the defined acetylated fragment for wound healing. Studies of the 43-residue parent and human reports using ambiguous TB4 or TB-500 labels cannot supply that missing fragment-specific comparison. No direct clinical comparison of defined Ac-LKKTETQ with GHK-Cu was identified in this review.

TB-500 in a rat tendon-repair study

Biçer and colleagues (2026) cut and repaired Achilles tendons in 32 rats, assigning eight per group to a supplier TB-500 product, BPC-157, both or injection liquid containing neither peptide. The publication did not report the control preparation’s ingredients or establish the TB-500 product’s peptide sequence and form. On day 30, four tendons per group were pulled until they broke. Repaired tendons from rats given the TB-500 product withstood more pulling force before breaking than tendons from rats given neither peptide (adjusted P=0.0406).

The study did not establish a strength difference between the active-treatment groups or an additional benefit from the combination. The product’s sequence and form remained unverified, so the result cannot yet be assigned to Ac-LKKTETQ. GHK-Cu was not tested.

Pharmacokinetics: metabolite detection and skin penetration

Rahaman and colleagues detected the TB-500 breakdown product Ac-LKK in rat urine through 72 hours. That interval depends on the analyte, urine collection and assay sensitivity. It does not establish a 72-hour half-life of the parent peptide, an active tissue concentration or human persistence. The scratch-assay result concerned a different metabolite, Ac-LKKTE.

Hostynek and colleagues (2010) measured copper after applying a copper–GHK preparation to removed human skin. Copper crossed the skin and was also retained in it over 48 hours. The assay did not identify intact GHK-Cu crossing or measure circulating concentrations in a treated person. These two experiments therefore cannot rank how long active TB-500 or GHK-Cu remains in human tissue.

Safety uncertainty remains tied to preparation and route

FDA’s 2026 TB-500 staff assessment found no adequate clinical safety information for the defined free base or acetate salt. It described concerns about peptide characterization, aggregation, impurities and possible immune reactions. The assessment states that neither is a component of an FDA-approved drug. A staff briefing for a compounding advisory committee is not a final approval decision.

FDA’s GHK-Cu entry specifically concerns injectable preparations and notes limited human data and possible immune reactions related to aggregation and peptide impurities. The topical studies summarized here do not determine injectable risk. Neither an absence of toxicity in a cell assay nor favorable tolerability in a small topical study can establish which compound is safer over long-term human exposure.

Frequently asked questions

Why not count full-length thymosin β4 trials as TB-500 trials?

The parent has 43 amino acids; the analytically identified TB-500 fragment has seven and carries an acetyl modification. A clinical result belongs to its tested sequence and formulation. Sharing part of a sequence does not establish equal activity, exposure or safety.

Does the rat tendon result prove that the acetylated fragment repairs tendons?

The repaired tendons from rats given the TB-500 product withstood more pulling force before breaking than tendons from rats given neither peptide. The publication did not establish the product’s sequence and chemical form. Four tendons per group underwent strength testing. The result cannot resolve whether Ac-LKKTETQ produced it.

Is 72-hour urine detection a dosing interval?

No. It concerns detection of the Ac-LKK metabolite in rat urine. It does not establish human persistence, an active tissue concentration or the parent peptide’s elimination half-life.

Do these studies establish a benefit from combining TB-500 and GHK-Cu?

No study identified for this review compared defined TB-500 plus GHK-Cu with each compound alone and a suitable control. Combining separate laboratory rationales cannot establish greater clinical benefit or acceptable combination safety.

TB-500 — full profile · Selected studies

GHK-Cu — full profile · Selected studies

Compare other compounds · Explore the guide previews

References

  1. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4(9):733–738. DOI: 10.1002/dta.1402.

    An independent analytical characterization established the acetylated fragment in a product named TB-500.

  2. Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2024;1235:124033. DOI: 10.1016/j.jchromb.2024.124033.

    Measured fragment metabolism in laboratory systems and rats and compared fibroblast responses; Ac-LKKTE alone improved scratch closure.

  3. U.S. Food and Drug Administration. FDA Evaluation of TB-500-Related Bulk Drug Substances (TB-500 Free Base and TB-500 Acetate). Briefing document for the Pharmacy Compounding Advisory Committee, July 23–24, 2026; evaluation dated May 15, 2026.

    The agency defines the acetylated fragment, differentiates its acetate salt and assesses the evidence and safety issues for compounding.

  4. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026;37(3):822–837. DOI: 10.52312/jdrs.2026.2951.

    After Achilles-tendon cutting and surgical repair in rats, the investigators measured the force needed to break the repaired tendons. The TB-500-labelled group withstood more force than the no-peptide vehicle group, but the publication does not establish its peptide sequence or chemical form.

  5. Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. The Biochemical journal. 1981;199(3):649–656. DOI: 10.1042/bj1990649.

    Solution experiments demonstrated multiple GHK-copper species and albumin competition.

  6. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS letters. 1988;238(2):343–346. DOI: 10.1016/0014-5793(88)80509-x.

    GHK-Cu increased collagen synthesis in cultured fibroblasts independently of cell-number change.

  7. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of vascular surgery. 1992;16(2):251–257. DOI: 10.1067/mva.1992.37086.

    The venous-ulcer trial did not establish greater ulcer-size reduction with the copper-tripeptide cream than with the carrying cream without peptide; silver sulfadiazine reduced ulcer size more than either cream.

  8. Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 1994;2(4):259–269. DOI: 10.1046/j.1524-475X.1994.20406.x.

    The standardized-care diabetic-ulcer comparison reported greater median plantar-ulcer area closure with GHK-copper gel; the acquired abstract lacked denominator and time point.

  9. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of facial plastic surgery. 2006;8(4):252–259. DOI: 10.1001/archfaci.8.4.252.

    The 13-completer post-laser study found no objective advantage but a favorable patient-rated skin-quality comparison.

  10. Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflammation Research. 2010;59(11):983–988. DOI: 10.1007/s00011-010-0214-4.

    The final skin-diffusion publication measured copper after applying a cuprate-diacetate preparation, providing a transport observation for copper in excised tissue.

  11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current agency web record, accessed October 13, 2026.

    Agency safety context distinguishes injectable GHK-Cu and the thymosin β4 fragment from other preparations.